Regeneron Pharmaceuticals (REGN) EBITDA Margin: History & Chart

Regeneron Pharmaceuticals, Inc.(REGN)

Biotechnology · Tarrytown, NY

$810.31+0.00 (+0.00%)

Delayed quote: Sep 8, 2026, 4:00 PM EDT

About Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.

Tarrytown, NY

15,410 employees

www.regeneron.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Leonard S. Schleifer

View full financials

REGN EBITDA Margin Metrics

EBITDA MARGIN

28.74%

EBITDA MARGIN AVG TTM

29.53%

EBITDA MARGIN AVG 3Y

31.18%

EBITDA MARGIN AVG 5Y

36.56%

EBITDA MARGIN AVG 10Y

36.62%

EBITDA MARGIN AVG 15Y

36.13%

EBITDA MARGIN AVG 20Y

22.86%

CURRENT VS TTM AVG

-2.68%

CURRENT VS 3Y AVG

-7.84%

CURRENT VS 5Y AVG

-21.39%

CURRENT VS 10Y AVG

-21.51%

CURRENT VS 15Y AVG

-20.46%

CURRENT VS 20Y AVG

+25.70%

NAME	MARKET CAP	EBITDA MARGIN	TTM	3Y	5Y
Regeneron Pharmaceuticals, Inc. (REGN)	$83.48B	28.74%	29.53%	31.18%	36.56%
HCA Healthcare, Inc. (HCA)vs ›	$87.04B	20.49%	20.06%	19.91%	20.05%
Elevance Health Inc. (ELV)vs ›	$87.17B	4.85%	5.33%	5.81%	6.32%
Cigna Corporation (CI)vs ›	$72.89B	4.28%	4.40%	4.95%	5.27%
GSK plc (GSK)vs ›	$97.25B	32.61%	26.78%	28.16%	28.64%
Boston Scientific Corporation (BSX)vs ›	$66.86B	26.60%	24.95%	24.24%	23.28%
Sanofi (SNY)vs ›	$103.62B	32.70%	28.59%	29.32%	32.36%
Cencora, Inc. (COR)vs ›	$63.17B	1.46%	1.44%	1.41%	1.40%
McKesson Corporation (MCK)vs ›	$104.10B	1.78%	1.58%	1.64%	1.66%
Stryker Corporation (SYK)vs ›	$105.97B	24.22%	25.63%	25.70%	26.23%

NAME

MARKET CAP

EBITDA MARGIN

TTM

Regeneron Pharmaceuticals, Inc. (REGN)

$83.48B

28.74%

29.53%

31.18%

36.56%

HCA Healthcare, Inc. (HCA)vs ›

$87.04B

20.49%

20.06%

19.91%

20.05%

Elevance Health Inc. (ELV)vs ›

$87.17B

4.85%

5.33%

5.81%

6.32%

Cigna Corporation (CI)vs ›

$72.89B

4.28%

4.40%

4.95%

5.27%

GSK plc (GSK)vs ›

$97.25B

32.61%

26.78%

28.16%

28.64%

Boston Scientific Corporation (BSX)vs ›

$66.86B

26.60%

24.95%

24.24%

23.28%

Sanofi (SNY)vs ›

$103.62B

32.70%

28.59%

29.32%

32.36%

Cencora, Inc. (COR)vs ›

$63.17B

1.46%

1.44%

1.41%

1.40%

McKesson Corporation (MCK)vs ›

$104.10B

1.78%

1.58%

1.64%

1.66%

Stryker Corporation (SYK)vs ›

$105.97B

24.22%

25.63%

25.70%

26.23%

EBITDA Margin FAQ

What is the EBITDA margin for Regeneron Pharmaceuticals, Inc. (REGN)?

The EBITDA margin for REGN stock is 28.74%.

Is Regeneron Pharmaceuticals, Inc.'s EBITDA margin high or low?

The EBITDA margin of 28.74% is 21% below its 5-year average of 36.56%, near the low end of its 5-year range (21.25%–66.52%).

What is the TTM average EBITDA margin for Regeneron Pharmaceuticals, Inc. (REGN)?

The TTM average EBITDA margin for REGN stock is 29.53%.

What is the 3Y average EBITDA margin for Regeneron Pharmaceuticals, Inc. (REGN)?

The 3Y average EBITDA margin for REGN stock is 31.18%.

What is the 5Y average EBITDA margin for Regeneron Pharmaceuticals, Inc. (REGN)?

The 5Y average EBITDA margin for REGN stock is 36.56%.

What is the 10Y average EBITDA margin for Regeneron Pharmaceuticals, Inc. (REGN)?

The 10Y average EBITDA margin for REGN stock is 36.62%.

What is the 15Y average EBITDA margin for Regeneron Pharmaceuticals, Inc. (REGN)?

The 15Y average EBITDA margin for REGN stock is 36.13%.

What is the 20Y average EBITDA margin for Regeneron Pharmaceuticals, Inc. (REGN)?

The 20Y average EBITDA margin for REGN stock is 22.86%.

DATE	EBITDA MARGIN
2026-06-30	35.99%
2026-03-31	21.25%
2025-12-31	26.39%
2025-09-30	30.99%
2025-06-30	33.04%
2025-03-31	23.73%
2024-12-31	29.47%
2024-09-30	34.97%
2024-06-30	33.56%
2024-03-31	27.52%
2023-12-31	33.88%
2023-09-30	39.15%
2023-06-30	35.45%
2023-03-31	34.86%
2022-12-31	41.46%
2022-09-30	44.83%
2022-06-30	48.34%
2022-03-31	45.90%
2021-12-31	54.81%
2021-09-30	55.62%
2021-06-30	66.52%
2021-03-31	46.67%
2020-12-31	50.71%
2020-09-30	48.49%
2020-06-30	36.64%
2020-03-31	41.36%
2019-12-31	39.17%
2019-09-30	45.39%
2019-06-30	23.30%
2019-03-31	38.69%
2018-12-31	39.47%
2018-09-30	39.82%
2018-06-30	40.78%
2018-03-31	39.93%
2017-12-31	36.23%
2017-09-30	39.83%
2017-06-30	39.82%
2017-03-31	35.53%
2016-12-31	30.64%
2016-09-30	32.02%
2016-06-30	26.11%
2016-03-31	29.34%
2015-12-31	23.13%
2015-09-30	36.32%
2015-06-30	36.07%
2015-03-31	34.45%
2014-12-31	32.59%
2014-09-30	27.90%
2014-06-30	36.22%
2014-03-31	32.46%
2013-12-31	36.59%
2013-09-30	41.47%
2013-06-30	36.67%
2013-03-31	36.95%
2012-12-31	37.49%
2012-09-30	49.50%
2012-06-30	32.75%
2012-03-31	13.21%
2011-12-31	-30.47%
2011-09-30	-48.80%
2011-06-30	-48.62%
2011-03-31	-30.30%
2010-12-31	12.31%
2010-09-30	-25.67%
2010-06-30	-16.57%
2010-03-31	-23.64%
2009-12-31	-35.61%
2009-09-30	1.96%
2009-06-30	-14.74%
2009-03-31	-19.22%
2008-12-31	-57.26%
2008-09-30	-26.16%
2008-06-30	-27.50%
2008-03-31	-22.99%
2007-12-31	-13.34%
2007-09-30	-160.49%
2007-06-30	-124.94%
2007-03-31	-195.05%
2006-12-31	-290.84%
2006-09-30	-157.12%
2006-06-30	-106.76%
2006-03-31	-98.06%
2005-12-31	-134.49%
2005-09-30	-188.04%
2005-06-30	-173.14%
2005-03-31	-151.04%
2004-12-31	16.76%
2004-09-30	-15.34%
2004-06-30	-31.13%
2004-03-31	44.47%
2003-12-31	401.13%
2003-09-30	-126.77%
2003-06-30	-230.28%
2003-03-31	-257.41%
2002-12-31	1304.80%
2002-09-30	-457.02%

DATE

EBITDA MARGIN

2026-06-30

35.99%

2026-03-31

21.25%

2025-12-31

26.39%

2025-09-30

30.99%

2025-06-30

33.04%

2025-03-31

23.73%

2024-12-31

29.47%

2024-09-30

34.97%

2024-06-30

33.56%

2024-03-31

27.52%

2023-12-31

33.88%

2023-09-30

39.15%

2023-06-30

35.45%

2023-03-31

34.86%

2022-12-31

41.46%

2022-09-30

44.83%

2022-06-30

48.34%

2022-03-31

45.90%

2021-12-31

54.81%

2021-09-30

55.62%

2021-06-30

66.52%

2021-03-31

46.67%

2020-12-31

50.71%

2020-09-30

48.49%

2020-06-30

36.64%

2020-03-31

41.36%

2019-12-31

39.17%

2019-09-30

45.39%

2019-06-30

23.30%

2019-03-31

38.69%

2018-12-31

39.47%

2018-09-30

39.82%

2018-06-30

40.78%

2018-03-31

39.93%

2017-12-31

36.23%

2017-09-30

39.83%

2017-06-30

39.82%

2017-03-31

35.53%

2016-12-31

30.64%

2016-09-30

32.02%

2016-06-30

26.11%

2016-03-31

29.34%

2015-12-31

23.13%

2015-09-30

36.32%

2015-06-30

36.07%

2015-03-31

34.45%

2014-12-31

32.59%

2014-09-30

27.90%

2014-06-30

36.22%

2014-03-31

32.46%

2013-12-31

36.59%

2013-09-30

41.47%

2013-06-30

36.67%

2013-03-31

36.95%

2012-12-31

37.49%

2012-09-30

49.50%

2012-06-30

32.75%

2012-03-31

13.21%

2011-12-31

-30.47%

2011-09-30

-48.80%

2011-06-30

-48.62%

2011-03-31

-30.30%

2010-12-31

12.31%

2010-09-30

-25.67%

2010-06-30

-16.57%

2010-03-31

-23.64%

2009-12-31

-35.61%

2009-09-30

1.96%

2009-06-30

-14.74%

2009-03-31

-19.22%

2008-12-31

-57.26%

2008-09-30

-26.16%

2008-06-30

-27.50%

2008-03-31

-22.99%

2007-12-31

-13.34%

2007-09-30

-160.49%

2007-06-30

-124.94%

2007-03-31

-195.05%

2006-12-31

-290.84%

2006-09-30

-157.12%

2006-06-30

-106.76%

2006-03-31

-98.06%

2005-12-31

-134.49%

2005-09-30

-188.04%

2005-06-30

-173.14%

2005-03-31

-151.04%

2004-12-31

16.76%

2004-09-30

-15.34%

2004-06-30

-31.13%

2004-03-31

44.47%

2003-12-31

401.13%

2003-09-30

-126.77%

2003-06-30

-230.28%

2003-03-31

-257.41%

2002-12-31

1304.80%

2002-09-30

-457.02%

EBITDA Margin: 28.74%

REGN EBITDA Margin

REGN Average EBITDA Margin Chart

REGN Current vs Average EBITDA Margin Chart

REGN EBITDA Margin Metrics

REGN Competitors' EBITDA Margin

Margin Comparison

EBITDA Margin Formula & Definition

EBITDA Margin FAQ

REGN EBITDA Margin History

Related Metrics